Matriptase cleaves EpCAM and TROP2 in keratinocytes, destabilizing both proteins and associated claudins by Wu, Chuan-Jin et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2020 
Matriptase cleaves EpCAM and TROP2 in keratinocytes, 
destabilizing both proteins and associated claudins 
Chuan-Jin Wu 
Michael Lu 
Xu Feng 
Gaku Nakato 
Mark C Udey 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
cells
Article
Matriptase Cleaves EpCAM and TROP2 in
Keratinocytes, Destabilizing Both Proteins and
Associated Claudins
Chuan-Jin Wu 1,*,† , Michael Lu 2,†, Xu Feng 3,†, Gaku Nakato 4,† and Mark C. Udey 5,*,†
1 Laboratory of Immune Cell Biology, National Cancer Institute, Bethesda, MD 20892, USA
2 Experimental Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA; lumi@mail.nih.gov
3 Retired from National Cancer Institute, Bethesda, MD 20892, USA; xuf99@yahoo.com
4 Kanagawa Institute of Industrial Science and Technology, Tonomachi, Kawasaki-ku, Kawasaki-shi,
Kanagawa 210-0821, Japan; op-nakato@newkast.or.jp
5 Dermatology Division, Department of Medicine, Washington University School of Medicine,
Saint Louis, MO 63110, USA
* Correspondence: wuchu@mail.nih.gov (C.-J.W.); udey@wustl.edu (M.C.U.);
Tel.: +1-301-760-7452 (C.-J.W.); +1-314-454-8547 (M.C.U.)
† Previous address: Dermatology Branch, Center for Cancer Research, National Cancer Institute,
Bethesda, MD 20892, USA.
Received: 17 March 2020; Accepted: 19 April 2020; Published: 21 April 2020


Abstract: The homologs EpCAM and TROP2, which both interact with claudin-1 and claudin-7,
are frequently coexpressed in epithelia including skin. Intestine uniquely expresses high levels of
EpCAM but not TROP2. We previously identified EpCAM as a substrate of the membrane-anchored
protease matriptase and linked HAI-2, matriptase, EpCAM and claudin-7 in a pathway that is pivotal
for intestinal epithelial cells (IEC) homeostasis. Herein, we reveal that TROP2 is also a matriptase
substrate. Matriptase cleaved TROP2 when purified recombinant proteins were mixed in vitro.
TROP2, like EpCAM, was also cleaved after co-transfection of matriptase in 293T cells. Neither
EpCAM nor TROP2 cleavage was promoted by protease-disabled matriptase or matriptase that
harbored the ichthyosis-associated G827R mutation. We confirmed that EpCAM and TROP2 are
both expressed in skin and detected cleavage of these proteins in human keratinocytes (HaCaT cells)
after the physiologic inhibition of matriptase by HAI proteins was relieved by siRNA knockdown.
Knockdown of EpCAM or TROP2 individually had only small effects on claudin-1 and claudin-7
levels, whereas elimination of both markedly diminished claudin levels. HAI-1 knockdown promoted
EpCAM and TROP2 cleavage accompanied by reductions in claudins, whereas HAI-2 knockdown
had little impact. Double knockdown of HAI-1 and HAI-2 induced nearly complete cleavage of
EpCAM and TROP2 and drastic reductions of claudins. These effects were eliminated by concurrent
matriptase knockdown. Decreases in claudin levels were also diminished by the lysosomal inhibitor
chloroquine and cleaved EpCAM/TROP2 fragments accumulated preferentially. We demonstrate
that TROP2 and EpCAM exhibit redundancies with regard to regulation of claudin metabolism
and that an HAI, matriptase, EpCAM and claudin pathway analogous to what we described in
IECs exists in keratinocytes. This study may offer insights into the mechanistic basis for matriptase
dysregulation-induced ichthyosis.
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1. Introduction
Matriptase (ST14) is a type II membrane serine protease that is expressed in embryonic and all adult
epithelia [1]. It is produced as a zymogen and becomes active after endoproteolytic cleavage by prostasin
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or matriptase itself [1–3]. Matriptase regulates epithelial barrier function in vitro and in vivo [4,5] and
dysregulation of matriptase causes defects in multiple epithelia. Matriptase-deficiency in mice leads to
malformation of stratum corneum and aberrant hair follicle development [6], and matriptase knockout
mice die perinatally due to dehydration resulting from severe skin barrier impairment. Mutations
in matriptase have been associated with two human syndromes; autosomal recessive ichthyosis
with hypotrichosis (ARIH) and ichthyosis, follicular atrophoderma, hypotrichosis, and hypohidrosis
(IFAH) [7,8]. Constitutive transgenic expression of matriptase in basal keratinocytes also induces
squamous carcinoma in mice [9].
Matriptase activity is tightly controlled by its cognate inhibitors HAI (hepatocyte growth factor
activator inhibitor)-1 (encoded by SPINT1) and HAI-2 (encoded by SPINT2) under physiological
conditions [10,11]. A mutation-based screen determined that HAI-1 regulates zebrafish skin
development and it has been demonstrated that HAI-1 promotes zebrafish skin epithelial integrity
via inhibition of matriptase [12]. HAI-1-deficient mice display severe ichthyosis and abnormal hair
development [13], and these phenotypes are associated with hyperactivation of matriptase [14].
Several matriptase substrates, including urokinase plasminogen activator (uPA), epidermal growth
factor receptor (EGFR), and hepatocyte growth factor (HGF), have been identified [4,15]. However,
detailed mechanisms by which these proteins contribute to physiological functions of matriptase has
often not been elucidated [1,4]. Impaired skin barrier function induced by matriptase mutations has
been attributed to defective filaggrin processing [8,16], but intracellular segregation of matriptase
and profilaggrin suggests the latter is not a direct matriptase substrate [17]. Changes in profilaggrin
processing are also unlikely to explain the matriptase deficiency-promoted hair follicle defect. A report
by Chen et al. [18] argued that matriptase regulates keratinocyte proliferation and early differentiation
in human skin. Dysregulated intercellular adhesion has been implicated in the impaired skin integrity
in zebrafish carrying HAI-1 mutations, but the putative matriptase substrate HGF, a known promoter
of epithelial-mesenchymal transitions, does not appear to play a major role [12]. Identification of
new matriptase substrates in keratinocytes may facilitate better understanding of matriptase’s role in
regulating skin homeostasis.
We previously reported that EpCAM (also known as CD326 or TROP1) is a physiological substrate
of matriptase in intestinal epithelial cells (IEC) [19]. Cleavage of EpCAM by matriptase between Arg80
and Arg81 led to dissociation of EpCAM/claudin-7 complexes and lysosomal degradation of EpCAM
and claudin-7 in IECs. The coordinated actions of HAI-2, matriptase, EpCAM and claudin-7 were
essential for intestinal epithelial homeostasis [19]. Studies of a mouse model has demonstrated that
EpCAM cleavage is enhanced and claudin-7 levels are diminished in intestinal epithelia of SPINT2
knockout mice which mimic congenital tufting enteropathy [20]. All of these proteins and/or their
homologs are also present in skin [6,13,21]. Adult intestinal epithelia is unusual in that it expresses
EpCAM but not its homolog TROP2, whereas skin expresses both proteins [21]. It has also been
reported that TROP2 interacts with claudin-7 and claudin-1, protecting these claudins from degradation
in corneal epithelial cells [21]. Similar to intestinal epithelium, skin constitutes a major barrier that
protects the organism from environmental and microbial insults. Herein we report that, like EpCAM,
TROP2 is a matriptase substrate. EpCAM and TROP2 had similar roles as regulators of claudins in
keratinocytes. We also describe a HAI-1(2)/matriptase/TROP2(1)/claudin cascade that is analogous to
the one that we reported in IECs [19]. This work may promote understanding of molecular mechanisms
behind physiological and pathological roles of matriptase and HAI-1 in skin.
2. Materials and Methods
2.1. Antibodies
Affinity-purified polyclonal rabbit anti-EpCAM antibody (Ab) has been described previously [22].
Monoclonal anti-mouse TROP2 antibody was generated by immunizing rabbits with recombinant
protein comprised of the extracellular region of mouse TROP2 fused by human IgG Fc.
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Polyclonal anti-TROP2, polyclonal goat anti-human HAI-1 (AF1048), sheep anti-matriptase (AF3946),
goat anti-mouse HAI-1 (AF1141), and goat anti-mouse HAI-2 (AF1107) Abs were purchased from R &
D Systems (Minneapolis, MN, USA). Anti-EpCAM (PA5-19832), anti-claudin-1 (717800), anti-claudin-7
(349100), and anti-occludin (711500) Abs were from Thermo Fisher Scientific (Carlsbad, CA, USA).
Rabbit anti-matriptase Ab (IM1014) was from EMD Millipore (Temecula, CA, USA). Polyclonal
anti-HAI-2 Ab (HPA011101), mouse anti-Flag mAb (clone M2) and anti-β-actin mAb (clone AC-15)
were from Sigma (St. Louis, MO, USA). Anti-E-cadherin mAb was from BD Biosciences (San Jose, CA,
USA), and rat anti-HA mAb (clone 3F10) was from Roche (Indianapolis, IN, USA).
2.2. Gene Expression Plasmids
pcDNA3-HAEpCAM has been described [22]. Plasmid expressing Flag-tagged human matriptase
was obtained from OriGene (Rockville, MD, USA). PCR-amplified HA-tagged mouse TROP2 cDNA
was cloned into pcDNA3. The constructed plasmid was verified by DNA sequencing. Matriptase
mutations were generated with a Quickchange Kit (Agilent Technologies, Santa Clara, CA, USA)
following the manufacturer’s instructions.
2.3. Cell Culture
HaCaT cells were purchased from AddexBio (San Diego, CA, USA). Caco-2 cells have been
described [22]. The 308 mouse keratinocyte cell line was kindly provided by Dr. Stuart Yuspa (National
Cancer Institute, Bethesda, MD, USA). HaCaT cells and 308 cells were grown in DMEM containing
10% fetal bovine serum (FBS). Caco-2 cells were grown in DMEM supplemented with 10% FBS, 15 mM
HEPES (pH 7.4) and non-essential amino acids.
2.4. Treatment of TROP2 with Recombinant Matriptase In Vitro
Catalytically active recombinant mouse matriptase was purchased from R&D Systems. Recombinant
mouse TROP2-hIgG protein was affinity-purified using protein A-sepharose (GE Healthcare, Pittsburgh,
PA, USA) from media of cultured 293F cells transfected with a plasmid encoding the mouse TROP2
extracellular domain fused to human IgG1 Fc fragment using Turbofect (Thermo Fisher Scientific). For the
in vitro cleavage assay, recombinant TROP2 was mixed with recombinant matriptase in 100 µL reaction
buffer (50 mM Tris, pH 8.5, 100 mM NaCl) and incubated at 37 ◦C for 1 h.
2.5. Transfection of 293 T Cells for Protein Expression
Empty vectors or vectors encoding HA-tagged EpCAM, HA-tagged TROP2, or Flag-tagged
matriptase were transfected into 293 T cells with Fugene 6 (Promega, Madison, WI, USA) following the
manufacturer’s instructions.
2.6. Knockdown of Protein Expression by siRNA Transfection
Matriptase siRNAs (HSS110268) were purchased from Thermo Fisher Scientific. Two human
EpCAM siRNAs and human SPINT2 siRNA have been described previously [19,22]. Human TROP2
and human SPINT1 siRNAs and mouse SPINT2 siRNAs were from Sigma. Negative control siRNA
was purchased from Sigma or Qiagen. HaCaT cells and 308 cells were transfected with negative
control siRNA, EpCAM siRNA, TROP2 siRNA, SPINT1 siRNA, SPINT2 siRNA or matriptase siRNA
duplexes using electroporation (Gene pulser, Bio-Rad Laboratories, Hercules, CA, USA) at 300 V for
20 s. Transfected cells were harvested and lysed 72 h after electroporation. Protein levels and/or protein
sizes were determined by Western blotting.
2.7. Gel Electrophoresis and Immunoblotting
Cells were lysed with RIPA lysis buffer and protein concentrations were determined using a
Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, USA) [22]. Cell lysates were cleared
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by centrifugation and resolved by SDS-PAGE (Nupage Bis-Tris gels, Thermo Fisher Scientific) and
proteins were visualized via Coomassie blue staining or immunoblotting. For immunoblotting, proteins
were transferred onto nitrocellulose membranes after SDS-PAGE separation and membranes were
subsequently incubated with the indicated Abs. Immunoreactive proteins on the blotted membrane
were visualized using horseradish peroxidase-conjugated secondary Ab (Jackson ImmunoResearch,
West Grove, PA, USA) and enhanced chemiluminescence (Thermo Fisher Scientific). Protein band
intensities were quantified using densitometry and NIH ImageJ software.
2.8. Mouse Study
C56BL/6 mice were obtained from Charles River Laboratories (Frederick, MD, USA) and housed
in a pathogen-free American Association for Laboratory Animal Care (AALAC)-accredited facility
on the NIH campus in Bethesda, MD, USA. Animal studies were carried out following guidelines
established by Research Animal Resource Center, NIH under the auspices of an animal study protocol
that had been approved by the National Cancer Institute Animal Care and Use Committee (ACUC).
2.9. Statistics
Probability (p) values for multiple group comparisons were calculated using two-way ANOVA.
P values for two group comparison were calculated using the Student’s t test. Aggregate results of
multiple experiments are displayed as means ± SEM.
3. Results
3.1. Differential Expression of HAI-1, HAI-2, EpCAM, and TROP2 in Skin and Intestine
We were interested in determining if the functional HAI/matriptase/EpCAM/claudin pathway
that we had identified in intestine [19] also exists in skin. We first analyzed expression of the major
components and their homologs in the pathway in mouse trunk skin using Western blotting. HAI-1,
HAI-2, matriptase and EpCAM were all detected in skin. In contrast to small intestine, skin expressed
not only EpCAM but also TROP2 (Figure 1A). Markedly less HAI-2 was expressed in skin as compared
with intestine, and the relative ratios of HAI-2/HAI-1 were more than 8 times less in skin than intestine
(Figure 1A and Figure S1). A similar pattern of expression of the related proteins was observed in
well characterized intestinal epithelial and keratinocyte cell lines (Caco2 and HaCaT cells, respectively;
Figure 1B).
3.2. Both EpCAM and TROP2 Modulate Associated Claudins in Keratinocytes
It has been reported that TROP2, like EpCAM, interacts with claudin-1 and caludin-7 and stabilizes
these claudins in corneal epithelial cells [21,22]. To determine if EpCAM and/or TROP2 influence
claudin-1 and/or claudin-7 in keratinocytes, we analyzed claudin expression after knocking down
EpCAM and/or TROP2 via siRNA transfection. In contrast to what we previously observed in Caco-2
and T84 IEC cells [22], efficient downregulation of EpCAM expression alone did not reduce claudin
1/7 levels in HaCaT cells (Figure 2A and Figure S2). We then proceeded to evaluate the impacts
on claudins by inhibition of both EpCAM and TROP2. To minimize the chance that the observed
impacts might be due to siRNA off-target effects, two or more different EpCAM and TROP2 siRNAs
were used in these experiments. Modest decreases in claudin-1 and claudin-7 levels was observed
in TROP2 siRNA transfected cells (Figure 2B). However, levels of both claudins (but not E-cadherin)
were dramatically diminished by simultaneous knockdown of EpCAM and TROP2 (Figure 2B and
Figure S2). It appears that reductions in claudin levels correlated with the knockdown efficacies of
different EpCAM and TROP2 siRNA combinations (Figure S2A). These results demonstrated that
EpCAM and TROP2 coordinately regulate selected claudins in keratinocytes.
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Figure 1. Expression of HAI-1, HAI-2, matriptase, EpCAM, and TROP2 in skin and intestine.
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Figure 2. Both EpCAM and TROP2 regulate claudin expression in keratinocytes. HaCaT cells were
transfected with control or EpCAM siRNAs (A), control, EpCA , TROP2, or EpCAM and TROP2
siRNAs (B) using electroporation. 72 h after transfection, cell lysates were prepared, resolved using
SDS-PAGE and im unoblotted with anti-EpC , a ti- 2, a ti-claudin-7 or anti-claudin-1 to
asse corresponding protein levels. β-actin l ing control.
3.3. Matriptase Cleaves TROP2 in vitro and Co-Expressed Matriptase Cleaves TROP2 in Cells.
Human TROP2 shares 48% amino acid identity and 62% amino acid similarity with human EpCAM.
In addition, a homologous arginine that we identified as the matriptase cleavage site for EpCAM
(Arg80) is present in huma TROP2 (Arg87) and murine TROP2 (Arg81) (Figure S3). To determine
if ma riptase cleaves TROP2 directly, we incubated recom inant mTROP2-IgG with recombinant
active atriptase. Mouse matriptase efficiently cleaved TROP2 and th cleavage resulted in a ~6 kDa
reduction in the molecular s ze of mouse TROP2-IgG (Fig re 3), consistent with cleavage at the site
Arg81, which is omologous to t e EpCAM cleavage site. Furthermore, co-expressed matriptase led to
cleavage of TROP2 in 293T cells in a dose-dependent manner (Figure 4A). These results demonstrated
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that like EpCAM, TROP2 is cleaved by matriptase in vitro and suggest that analogous cleavage also
occurs in cells and presumably in vivo. EpCAM (Figure 4B) and TROP2 (Figure 4C) cleavage was not
promoted by the protease-inactive matriptase S805A mutant [23], indicating that matriptase protease
activity is required for EpCAM and TROP2 cleavage in cells. Matriptase G827R mutation has previously
been identified in some ARIH patients [7]. Interestingly, the ARIH-associated G827R mutation also
prevented matriptase cleavage of EpCAM (Figure 4B) and TROP2 (Figure 4C).
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epitope-tagged proteins were analyzed via Western blotting using anti-HA and anti-Flag. Representative
data from 1 of 3 experiments is shown.
3.4. HAI-1 and HAI-2 Attenuate EpCAM and TROP2 Cleavage and Protect Claudins in Keratinocytes
We next determined if matriptase-mediated proteolysis of endogenous EpCAM and TROP2
occurred in HaCaT cells. Despite observation of little cleavage of EpCAM and TROP2 in untransfected
(Figure 1B) an control siRNA t ansfected H CaT cells (Figure 5A), EpCAM cleavage
cleav ge were readily appare t n HAI 1 kn ckdown c lls (Figure 5A). This was accompanied
by claudin-1 d claudin-7 own egulation (Figure 5A). Sm ll mounts of EpCAM cleavage nd
TROP2 cleavage were also o ser ed in mouse 308 keratinocytes (Figur S4). In striking contrast to
our previous observat ons of ramat c increases in EpCAM cleavage and reductio s in claudin-7
levels in HAI-2 knockdown IEC cel [19], knockdown of HAI-2 in keratinocytes did not induce
EpCAM/TROP2 cleavage or reduce claudin levels (HaC T cell, Figure 5B and Figure S5), or slightly
increased EpCAM/TROP2 cleavage (308 cells, Figure S4). These results are co sisten with notion tha
HAI-1 plays a more prominent role than HAI-2 in inhibiting matriptase and in regulating matriptase
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function in skin than in intestine [13,14,17]. Interestingly, simultaneous inhibition of both HAI-1
and HAI-2 led to marked increases in EpCAM and TROP2 cleavage and striking downregulation of
claudin-1 and claudin-7 (Figure 5B and Figure S5), implying that HAI-1 and HAI-2 are redundant or
cooperative in inhibiting matriptase action on endogenous substrates in keratinocytes. Again, the
6–10 kD molecular size reduction (Figures 4A,C and 5A,B) in TROP2 after cleavage suggested that
matriptase cleaves hTROP2 at the homologous EpCAM cleavage site in TROP2, Arg87 (Figure S3).
However, it is possible that matriptase cleaves TROP2 at one or two additional sites that are close to
Arg87, since multiple cleavage products were seen in several experiments (Figures 4A,C and 5A,B).
Potentially relevant to this, there are at least two lysine/arginine’s (Lys84 and Arg92) that are located in
close proximity to Arg87 in hTROP2 (Figure S3).
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Figure 5. HAI-1 and HAI-2 regulate EpCAM and TROP2 cleavage and claudin levels. HaCaT cells
were transfected using electroporation with control siR A or one of two different SPINT1 siRNAs
(siSPINT1-1 and siSPINT1-2) (A), control, SPINT1, SPINT2, r I T1, and SPINT2 siRNAs (B). After
72 h, cell lysates w re p ared, subjected to electroph d analyzed via W stern blotting for
HA1-1, HAI-2, matriptase, EpCAM, TROP2, claudin-1, clau i E-cadherin. β-actin was used as
a loading control. Representative data from 1 of 3–4 experi ents is shown.
3.5. Matript se Cleaves EpCAM and TROP2 to Induce Degr of EpCAM, TROP2 and Claud s in
Lysosomes in Keratinocytes
To address the possibility that HAI-1 and HAI-2 were acting via inhibition of serine proteases other
than matriptase [17,24], we analyzed EpCAM and TROP2 cleavage in HaCaT cells after transfecting
matriptase siRNA along with SPINT1 and SPINT2 siRNAs (Figure 6A). Knockdown of matriptase
eliminated HAI-1/2 inhibition-induced EpCAM and TROP2 cleavage and claudin downregulation
(Figure 6A), suggesting that HAI-1/2 regulation of EpCAM/TROP2 and claudins in keratinocytes is via
inhibition of matriptase. These results also revealed that, like EpCAM, TROP2 is an intrinsic matriptase
substrate in cells. Marked decreases in total EpCAM and TROP2 (but not E-cadherin) levels were
observed in the HaCaT cells that were transfected with SPINT1 and SPINT2 siRNAs (Figures 5B and
6A). We previously demonstrated that matripase-cleaved EpCAM and claudins disassociate, internalize
and are degraded in lysosomes [19,22], and it was reported that TROP2 knockdown-induced claudin
Cells 2020, 9, 1027 8 of 12
reductions are not transcription-related [21]. To determine whether the loss of EpCAM/TROP2 and/or
claudin is caused by protein degradation in lysosomes, we treated SPINT1/2 siRNA-transfected cells
with chloroquine. This lysosomal inhibitor largely rescued claudin-1 and claudin-7 losses resulting
from HAI-1 and HAI-2 inhibition (Figure 6B,C). In addition, chloroquine increased accumulation
of cleaved EpCAM and cleaved TROP2, but not full-length forms of these proteins (Figure 6B,C).
These results demonstrated that matriptase-cleaved EpCAM and TROP2 proteins are unstable in
keratinocytes, that they are degraded in lysosomes, and that they lose their ability to stabilize claudins.
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Figure 6. HAIs act via matriptase to regulate degradation of EpCAM, TROP2, and claudins in lysosomes.
HaCaT cells were transfected using electroporation with control or SPINT1 plus SPINT2, matriptase, or
SPINT1, SPINT2 plus matriptase siRNAs (A), or control or SPINT1 and SPINT2 siRNAs (B). Before
being harvested at 72 h after transfection (A,B), cells were treated with or without 100 µM chloroquine
for 20 h (B). RIPA cell lysates were resolved using SDS-PAGE and immunoblotted with anti-HAI-1,
anti-HAI-2, anti-matriptase, anti-EpCAM anti-TROP2, anti-claudin-1, or anti-claudin-7. β-actin was
used as a loading control. Representative data from 1 of 5 experiments is shown. (C) Band intensities
corresponding to full-length (FL) EpCAM, FL TROP2, claudin-1 and claudin-7 (left panel) and cleaved
EpCAM and cleaved TROP2 (right panel) were quantified and normalized to β-actin. Data are plotted
as ratios (means ± SEM) relative to corresponding untreated siControls (n = 5). A two-way ANOVA
was used to calculate p values for multiple group comparisons to assess mean differences between
groups (* p < 0.05, ** p < 0.01, *** p < 0.001 or 0.0001, n.s. p > 0.05).
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4. Discussion
In this study, we confirmed that EpCAM and TROP2 are present in keratinocytes, and we
demonstrated that both EpCAM and TROP2 regulate the levels of claudin-1 and claudin-7 in
these cells. TROP2 was cleaved by matriptase in vitro and TROP2 cleavage was promoted by
matriptase overexpression in cells, indicating that, like EpCAM, TROP2 is a substrate of matriptase.
Matriptase cleavage induced lysosomal degradation of EpCAM/TROP2 and associated claudins.
Matriptase-mediated cleavage of EpCAM and TROP2 and downregulation of claudins was inhibited by
HAI-1 and HAI-2 in keratinocytes. Thus, analogous HAI/matriptase/EpCAM/claudin pathways exist in
keratinocytes and IECs. The pathways in each tissue have distinct features, however. In keratinocytes,
both EpCAM and TROP2 are present, and both regulate claudins. HAI-2 is the dominant HAI regulator
of matriptase-mediated cleavage of EpCAM in IECs [19,20], whereas HAI-1 plays a more important
role than HAI-2 in regulating matriptase cleavage of EpCAM/TROP2 in keratinocytes. Claudin-7 is the
major claudin that is modulated by matriptase and HAIs in IECs [11,19]. In keratinocytes, claudin-1 is
also regulated by these proteins.
Patients with EpCAM mutations and EpCAM knockout mice display severe intestinal dysfunction,
but they do not exhibit obvious extra-intestinal abnormalities [25–27]. One possible explanation is that
EpCAM is strongly expressed in the intestine while TROP2 is virtually absent. In most other epithelia,
both EpCAM and TROP2 are present, and in these epithelia one protein may compensate for the other.
TROP2 is highly homologous to EpCAM, and both TROP2 and EpCAM interact with claudin-7 and
claudin-1 [21,22]. The present study demonstrates that both EpCAM and TROP2 regulate claudins in
keratinocytes. We have determined that transgenic expression of TROP2 in murine intestine was able
to at least partially reverse intestinal dysfunction in EpCAM KO mice, enabling survival (Nakato G
and Udey MC, unpublished data). TROP2’s ability to interact with and stabilize claudins may explain
this observation. It is possible that TROP2 and EpCAM could also functionally compensate for each
other in skin.
We have also shown that both siRNA inhibition of EpCAM and TROP2 expression and matriptase
cleavage of EpCAM and TROP2 led to downregulation of claudin-1 and claudin-7 in keratinocytes.
It is unknown whether or not claudin-7 plays an important role in skin biology, but studies of knockout
mice demonstrated that claudin-1 is critical for skin barrier function. Claudin-1 knockout mice die
within 1–2 days after birth because of dehydration caused by skin barrier dysfunction [28]. We observed
that inhibition of HAI-1 in HaCaT cells led to activation of matriptase and decreases in claudin-1 and
claudin-7 levels. We propose that alterations in claudin-1 stability contributes to, or is responsible for,
HAI-1 deficiency-induced ichthyosis.
EpCAM and TROP2 constitutively interact with claudin-1 and claudin-7 [21,22,29]. We previously
showed that matriptase co-localizes with EpCAM in intestinal epithelia and that matriptase interacts
with EpCAM in intestinal epithelial cells [19]. Protein structural studies have demonstrated that
both EpCAM and TROP2 form homodimers [30,31]. Also, it has been reported claudins may homo-
or hetero-oligomerize [32,33] and that claudin-1 and claudin-7 interact [22,34]. This suggests that
EpCAM and TROP2 could be present in complexes with the potential to interact with, and be
regulated by, matriptase. It is not known whether or not EpCAM and TROP2 heterodimerize and
if matriptase interacts with EpCAM and/or TROP2 directly in skin cells. More details regarding
matriptase/EpCAM/TROP2/claudin complex formation and complex regulation by other proteins such
as HAI-1/2 await further studies.
In contrast to what we observed in the IEC cell line Caco2 [19], HAI-2 inhibition by siRNA
in keratinocytes minimally increased EpCAM and TROP2 cleavage and claudin loss. Two recent
studies demonstrated that EpCAM was robustly cleaved and claudin-7 was markedly downregulated
in the intestinal epithelia of SPINT2 KO mice [20,35]. The reasons for the discrepancy regarding
HAI-2’s role in inhibiting matriptase cleavage of TROP proteins in IECs and in keratinocytes are
unknown. Marked differences in HAI-1/HAI-2 protein level ratios in skin and intestine (Figure 1A
and Figure S1) may be relevant. Our siRNA transfection experiment suggested that HAI-1 plays
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a more prominent role in inhibiting matriptase in keratinocytes than HAI-2 does. These results
are consistent with the concept that HAI-2 is more important than HAI-1 in intestine, and that the
reverse is true in skin [11,13,20,36]. We detected much more EpCAM and TROP2 cleavage and
claudin loss in double knockdown cells than in single SPINT1 siRNA- or SPINT2 siRNA- transfected
cells. These results indicate that HAI-1 and HAI-2 may play a redundant or cooperating role in
inhibiting matriptase in keratinocytes. While it is known that both HAI-1 and HAI-2 inhibit matriptase
activity, the precise roles of these homologous proteins in regulating matriptase are currently unclear.
Identification of EpCAM and TROP2 as physiologically relevant substrates of matriptase may create
opportunities to study mechanistic aspects of matriptase regulation in detail. Understanding the
molecular mechanisms for activation and inhibition of matriptase is key to designing strategies to treat
matriptase dysregulation-induced conditions.
Finally, it is not clear why mutations in matriptase cause ichthyosis. Studies using synthetic
peptide substrates suggested that the G827R mutation inactivates protease activity [23,37]. Consistent
with this, in this study we showed that the matriptase G827R mutant also fails to promote cleavage of
the physiological substrates EpCAM and TROP2. Additional studies are needed to further evaluate
the functional importance of the HAI/matriptase/TROP/claudin pathway in skin and to determine
if some rare, or perhaps common, skin diseases are a consequence of dysregulation of this pathway.
EpCAM, TROP2, claudins, matriptase, and HAI proteins have all been reported roles in cancer [38–45].
Our demonstration of the physiological relationship among these proteins may offer clues for a better
understanding of their roles in cancer at molecular level.
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